793 abstracts found.



Results filter

Identification and triage of patient and carer needs: a clinician-rated tool for the clinic or surgery

Year:

Session type: ,

Miriam Johnson1

1University of Hull, Hull, UK


Novel intrapatient dose escalation phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 in BRCA1/2 and non-BRCA1/2 mutation patients with advanced cancers

Year:

Session type: ,

Timothy Yap1,2

1The Institute of Cancer Research, London, UK,2Royal Marsden Hospital, London, UK


Operationalising needs-based assessment

Year:

Session type: ,

David Currow1

1Flinders University, Adelaide, Australia


E-cigarettes and policy’

Year:

Session type:

Linda Bauld1

1Cancer Research UK, London, UK,2University of Stirling, Stirling, UK


Benefits and Harms of Preventive Therapy for Cancer

Year:

Session type: ,

Jack Cuzick1

1Queen Mary University of London, London, UK




Devising the ideal test for early diagnosis of cancer: lessons from the oesophagus

Year:

Session type: ,

Rebecca Fitzgerald1

1Univeristy of Cambridge, Cambridge, UK




How many cancers can we prevent through dietary modifications?

Year:

Session type: ,

Paolo Boffetta1

1Icahn School of Medicine at Mount Sinai, New York NY, USA


Hormone Therapy for Prostate Cancer

Year:

Session type: ,

Charles Sawyers1

1Memorial Sloan Kettering Cancer Center, New York, NY, USA


Circulating tumour cells and plasma DNA for non-invasive monitoring of cancers during their treatment

Year:

Session type: ,

Michael Speicher1

1Medical University of Graz, Graz, Austria




Working together in the Genomics Era – Lessons from the GTEOC study 

Year:

Session type: ,

Marc Tischkowitz1

1University of Cambridge, Cambridge, UK


The future role of primary care in cancer control – survivorship care

Year:

Session type: ,

Annette Berendsen1

1University of Groningen, Groningen, The Netherlands


microRNA mechanism and its involvement in DNA damage response pathway

Year:

Session type: ,

Martin Bushell1

1MRC Toxicology Unit, Leicester, UK


Selecting rational combinations for cancer and delivering early phase clinical trials in the UK.

Year:

Session type:

Hazel Jones1

1CRUK Centre for Drug Development, London, UK


Trends in electronic cigarette use in England

Year:

Session type: ,

Robert West1

1UCL, London, UK


Combinations Alliance from an Industry Perspective

Year:

Session type:

Susan Galbraith1

1AstraZeneca Oncology Innovative Medicines, Cambridge, UK


DEBIOC: A Combinations Alliance Study of AZD8931 in combination with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma

Year:

Session type: ,

Anne Thomas1

1University of Leicester, Leicester, UK




Physical activity, obesity and cancer

Year:

Session type: ,

Martin Wiseman1,2

1WCRF International, London, UK,2University of Southampton, Southampton, UK


Technological Developments in Radiotherapy

Year:

Session type: ,

Uwe Oelfke1

1Institute of Cancer Research, Sutton, Surrey, UK




Protective packaging for DNA: the role of the PBAF and INO80 chromatin remodelling complexes in maintaining genome stability

Year:

Session type: ,

Jessica Downs1

1Genome Damage and Stability Centre, Falmer, Brighton, UK


The genomic landscape of paediatric brain tumours – Recent advances

Year:

Session type:

David Jones1

1German Cancer Research Centre (DKFZ), Heidelberg, Germany




Role of the BRCA1:BARD1 Ubiquitin Ligase Activity in DNA repair.

Year:

Session type: ,

Jo Morris1

1University of Birmingham, West Midlands, UK




Phylogenetic analysis reveals divergent modes of clonal spread and intraperitoneal mixing in high grade serous ovarian cancer

Year:

Session type: ,

Sohrab Shah1,2

1BC Cancer Agency Research Centre, Vancouver, BC, Canada,2University of British Columbia, Vancouver, BC, Canada


What can observational studies tell us about early diagnosis of symptomatic cancer?

Year:

Session type: ,

Willie Hamilton1

1University of Exeter, Exeter, UK


Reducing prostate cancer progression and mortality: what you can do to reduce your risk

Year:

Session type:

Stacey Kenfield1,2

1University of California, San Francisco, San Francisco, CA, USA,2Harvard School of Public Health, Boston, MA, USA


Can we do RCTs of interventions to expedite the diagnosis of symptomatic cancer? And should we?

Year:

Session type: ,

Richard Neal1

1Bangor University, Bangor, UK


Big data and patient reported outcome measures (PROMs)

Year:

Session type: ,

Amy Abernethy1

1Flatiron Health, New York, NY, USA


Fc-mediated depletion of Tregs via ipilimumab-dependent ADCC in advanced melanoma patients

Year:

Session type:

Emanuela Romano1,2

1Dept. of Oncology, University Hospital of Lausanne, Lausanne, Switzerland,2Ludwig Cancer Research Center, Lausanne, Switzerland


Investigating the genomic landscape of brain tumours using metabolic imaging

Year:

Session type:

Kevin Brindle1

1University of Cambridge, Cambridge, UK


It takes a team: the importance of integration between primary care and cancer specialist care.

Year:

Session type: ,

Eva Grunfeld1

1Ontario Institute for Cancer Research, Toronto, Canada,2University of Toronto, Toronto, Canada


How do health economists value personalised medicine in oncology?

Year:

Session type: ,

Maarten IJzerman1

1University of Twente, Enschede, The Netherlands


The Role of KSRP in the Alternative Splicing of the Fibroblast Growth Factor Receptor 2 in Triple Negative Breast Cancer

Year:

Session type:

Theme:

Kiashanee Moodley1,Kurt Lightfoot2,Caroline Dickens1,Therese Dix-Peek1,Juan Valcárcel2,Raque Duarte1,Gwendal Dujardin2

1Department of Internal Medicine, Faculty of Health Sciences, Johannesburg, South Africa,2Gene Regulation, Stem Cells and Cancer, Centre de Regulació Genòmica, Barcelona, Spain


An assessment of PARP-1 inhibition in combination with external beam x-radiation in the treatment of neuroblastoma

Year:

Session type:

Theme:

Iain Hyndman1,Donna Nile1,Colin Rae1,Mark Gaze2,Robert Mairs1

1Radiation Oncology, Institute of Cancer Sciences, Glasgow, UK,2Great Ormond Street Hospital, London, UK


Characterisation of the mucin receptor MUC1 in the progression to oesophageal cancer and potential for antibody directed therapy.

Year:

Session type:

Theme:

Mohammed Adil Butt2,1,Hayley Pye1,SUR Khan1,I Puccio1,H Reinert1,E Bloom1,M Gandy1,M Rashid7,M Deonarain3,D Swallow6,M Banks2,M Rodriguez-Justo5,R Hamoudi1,M Novelli5,LB Lovat1,2,RJ Haidry2,D Oukrif5

1Department for Tissue & Energy, University College London, London, UK,2Upper Gastrointestinal Service, University College London, London, UK,3Antikor BioPharma, Stevenage Bioscience Catalyst, Stevenage, UK,4Antikor BioPharma, Stevenage Bioscience Catalyst, Stevenage, UK,5Department of Pathology, University College London, London, UK,6Genetics, Evolution & Environment, Division of Biosciences, University College London, London, UK,7Department of Oncology, UCL Cancer Institute, London, UK


Can we use N-acetyl-l-aspartyl-l-glutamate peptidase-like 2 to target drugs to cancer cells?

Year:

Session type:

Theme:

Hannah Luxton1,B Simpson1,J Kay1,S Menon3,M Brown2,N Clarke2,H Whitaker1

1Molecular Diagnostics and Therapeutics Group, London, UK,2Genito Urinary Cancer Research Group, Institute for Cancer Sciences, Manchester, UK,3Bioinformatics Core Facility, Cancer Research UK Cambridge Institute, Cambridge, UK


How many lives will bowel cancer screening save if we improve participation in Merseyside? 

Year:

Session type:

Theme:

Matthew Saunders1,Daniel Seddon2

1Public Health England, Cjesjire&Merseyside, UK,2NHS England North, London, UK


“Identifying novel transcriptional downregulators of MCL-1 to induce apoptosis in pancreatic cancer”

Year:

Session type:

Theme:

Mateus Milani1

1University of Liverpool, Liverpool, UK


PRospective observational assessment of the effectiveness of Enzalutamide treatment in patients with Metastatic castration-resIstant proState cancEr in a real-world clinical practice setting: the ongoing PREMISE study

Year:

Session type:

Theme:

Heather Payne1,Michael Borre2,Richard Davidson3,Robert Snijder4,Maria De Santis5

1University College London Hospitals, Department of Oncology, London, UK,2Aarhus University Hospital, Department of Urology, Aarhus, Denmark,3Astellas Pharma EMEA, Chertsey, UK,4Astellas Pharma Global Development, Leiden, The Netherlands,5University of Warwick, Cancer Research Unit, Coventry, UK


Comparison of different NGS library construction methods for single cell sequencing

Year:

Session type:

Theme:

Peter Hahn1,Rumeysa Akinci-Tolun1,Isabell Haupt1,Ioanna Andreou1,Christian Korfhage1,Nan Fang1

1QIAGEN GmbH, QIAGEN Strasse, Hilden, Germany


Primary versus metastasis using iontorrent next generation sequencing (PRIMINGS)

Year:

Session type:

Theme:

David Moore1,2,Luke Martinson1,William Dalleywater2,Jacqui Shaw1,John Le Quesne1,2

1University of Leicester, Leicester, UK,2University Hospitals Leicester, Leicester, UK


A HER2 selective theranostic agent for surgical resection guidance and photodynamic therapy.

Year:

Session type:

Theme:

Hayley Pye1,Mohammed Adil Butt1,2,Halla Reinert1,Antoine Maruani3,Jared Marklew4,Joao Nunes3,Maryam Qurashi1,5,Laura Funnel1,Abi May1,James Baker3,Mark Smith3,Stephen Caddick3,Gokhan Yahioglu4,5,Mahendra Deonarain4,Vijay Chudasama3,Laurence Lovat1,2

1Department for Tissue & Energy, University College London, London, UK,2Upper Gastrointestinal Service, University College Hospital, London, UK,3Department of Chemistry, University College London, London, UK,4Antikor BioPharma, Stevenage Bioscience Catalyst, London, UK,5Department of Chemistry, Imperial College London, London, UK


Oncology and Haematology Clinical Trials (OHCT) -What is the Role of the Clinical Trial Practitioner (CTP)?

Year:

Session type:

Theme:

Harriet Jones1,Rachel Todd1,Piranavan Sucindran1,Nicholas Gomm1

1Guy’s and St Thomas’ Foundation NHS Trust, London, UK


Dynamic contrast-enhanced MRI to predict treatment response to neoadjuvant chemotherapy in muscle invasive bladder cancer: MARBLE study

Year:

Theme:

Rachel Pearson1,2,Emily Fitzgerald3,Pete Thelwall4,Jim Snell2,Jill McKenna2,Piotr Pieniazek5,Rhona McMenemin2,Ashraf Azzabi2,Ian Pedley2,Rakesh Heer1,Ross Maxwell1,Ruth Plummer1,2,Herbie Newell1,John Frew2

1Northern Institute for Cancer Research, Newcastle upon Tyne, UK,2Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK,3Newcastle University Medical School, Newcastle upon Tyne, UK,4Newcastle MR Centre, Campus of Ageing and Vitality, Newcastle upon Tyne, UK,5Department of Radiology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK


Apical SLC9A3R1 links high-grade colorectal cancer morphology to genomic instability

Year:

Session type:

Theme:

Jane McClements1,Ravi Deevi1,Arman Javadi1,Lisa Rainey1,Maurice Loughrey2,1,Frederick Campbell1

1Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, UK,2Department of Histopathology, Royal Victoria Hospital, Belfast, UK


Key role of AGO2 and the 8q24 amplicon in regulation of microRNA biogenesis in cancer

Year:

Session type: , ,

Theme:

Laura Winchester1,Simon Wigfield1,Syed Haider1,Alan McIntyre1,Adrian Harris1,Francesca Buffa1

1University of Oxford, Oxford, UK


Circulating RNA in prostate cancer reveals novel androgen regulated genes that predict poor outcome

Year:

Session type:

Theme:

Benjamin Thomas1,Jonathan Kay2, Suraj Menon1, Sarah Vowler1, Sarah Dawson1, Hayley Luxton1, Thomas Johnson1, Charlie Massie1, Michelle Osbourne1, Anne Warren3, Keith Burling3, Andy Lynch1,Anne George4, Marie Corcoran4, Johannah Burge4, Sara Stearn4, Alastair Lamb1, Greg Shaw1, David Neal1, Hayley Whitaker3

1CRUK Cambridge Institute, Cambridge, UK,2University College London, London, UK,3Addenbrookes Hospital, Cambridge, UK,4University of Cambridge, Cambridge, UK,5University of Oxford, Oxford, UK


Quit With Us: A pro-active community based smoking cessation intervention 

Year:

Session type:

Theme:

Tim Banks1,Maura Matthews1,Gail Hughes1,Jess Bridgeman1,Ian Lewis1

1Tenovus Cancer Care, Cardiff, Wales, UK


Research by researchers selected by patients: Research by patients selected by researchers

Year:

Session type:

Theme:

Ian Lewis1,Anita Howman1,Corinne Squire2,Sue Bevan2,Stephen Thomas1

1Tenovus Cancer Care, Cardiff, Wales, UK,2Cardiff University, Cardiff, Wales, UK


Control of cell migration in normal and neoplastic neural stem cells via a PML/EZH2-mediated regulatory loop

Year:

Session type:

Theme:

Deli A1,2,Valeria Amodeo1,2,Joanne Betts1,2,Stefano Bartesaghi1,2,Mikaella Vouri1,2,Rozita Roshani1,2,Sarah Oberndorfer1,2,Maya Shaked-Rabi3,David Dinsdale4,Pierluigi Nicotera5,Chris Jones6,David Michod1,2,Sebastian Brandner3,Paolo Salomoni1,2

1UCL Cancer Institute, London, UK,2Samantha Dickson Brain Cancer Unit, London, UK,3UCL Institute of Neurology, London, UK,4MRC Toxicology Unit, Leicester, UK,5DZNE, Bonn, Germany,6Institute of Cancer Research, Sutton, UK,7UCL Institute of Child Health, London, UK


Decreased Serum Thrombospondin-1 Levels in Pancreatic Ductal Adenocarcinoma Patients: An Early Indicator of Disease or Diabetes Mellitus Development?

Year:

Session type:

Theme:

Claire Jenkinson1,2,Victoria Elliott1,2,Anthony Evans1,2,Lucy Oldfield1,2,Rosalind Jenkins3,John Timms4,Darragh O’Brien4,Sophia Apostolidou4,Aleksandra Gentry-aharaj4,Evangelia Fourkala4,Ian Jacobs4,5,Usha Menon4,Trevor Cox1,Fiona Campbell6,Robert Sutton1,2,Stephen Pereira7,David Tuveson8,Kevin Park3,William Greenhalf1,2,John Neoptolemos1,2

1Department of Molecular and Clinical Cancer Medicine, Liverpool, UK,2National Institute for Health Research Liverpool Pancreas Biomedical Research Unit, Liverpool, UK,3MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, Liverpool, UK,4Department of Women’s Cancer, Institute for Women’s Health, London, UK,5Faculty of Medical & Human Sciences, 1.018 Core Technology Facility, Manchester, UK,6Department of Pathology, Liverpool, UK,7Institute for Liver and Digestive Health, London, UK,8Cold Spring Harbor Laboratory, New York, USA


A randomised trial of interventions to increase uptake of cervical screening among 25 year old non-attenders; final results of the STRATEGIC Trial.

Year:

Session type: , ,

Theme:

Henry Kitchener1,Matthew Gittins2,Carly Moseley1,Margaret Cruickshank3,Samantha Fletcher1,Jamie Oughton1,Rebecca Albrow1,Emma Crosbie1,Chris Roberts2

1Institute of Cancer Sciences, University of Manchester, Manchester, UK,2Institute of Population Health, University of Mancchester, Manchester, UK,3Department of Obstetrics and Gynaecology, University of Aberdeen, Aberdeen, UK